Hypopituitarism

The Lancet, Journal Year: 2024, Volume and Issue: 403(10444), P. 2632 - 2648

Published: May 9, 2024

Language: Английский

---

Decompensated Cirrhosis with Hepatopulmonary Syndrome in a Patient with Interrupted Treatment for Hypopituitarism: A Case Report

Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

A 32-year-old man presented with cirrhosis. At 8 years of age, he underwent resection a craniopharyngioma, which resulted in panhypopituitarism. He self-interrupted hormone replacement therapy at 20 age. Computed tomography revealed severe fatty liver and An endocrinological evaluation Further assessment diagnosis hepatopulmonary syndrome. Home oxygen were initiated. Despite these efforts, poorly controlled hypothalamic obesity led to failure, the patient is currently awaiting transplantation. Liver cirrhosis associated long-term panhypopituitarism may have poor prognosis even therapy.

Language: Английский

---

Clinical Management of Postoperative Growth Hormone Deficiency in Hypothalamic-Pituitary Tumors

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(15), P. 4307 - 4307

Published: July 24, 2024

The present review focuses on growth hormone (GH) deficiency in pediatric and adult patients following surgery for hypothalamic-pituitary tumors, with a special emphasis replacement therapy recombinant human (rhGH). symptoms metabolic changes associated GH are reviewed, the potential risks therapeutic outcomes of rhGH treatment these discussed. This emphasizes importance normalization children improvement quality life (QoL) health adults. Aspects related to efficacy, safety, dosage, duration treatment, QoL this population analyzed. need regular follow-up dose adjustment maintain optimal IGF-I levels is emphasized, as individualized assessment collaboration specialized multidisciplinary medical team make appropriate decisions. Furthermore, continuous necessary optimize clinical patient population.

Language: Английский

---

Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 6, 2024

Introduction Adult growth hormone deficiency (AGHD) is associated with a high prevalence of metabolic syndrome (MS), which contributes to the unfavorable cardiovascular risk profile in these patients. Insulin like factor-1 (IGF-1) widely used biomarker, however it does not always reflect cardiometabolic and has poor relationship clinical efficacy endpoints. Consequently, there an unmet need for biomarkers monitor responses GH-replacement. Afamin hormone-like glycoprotein, expressed liver. Higher afamin levels are strongly MS insulin resistance (IR). Although both IR very common AGHD, been investigated Purpose To investigate as potential biomarker patients AGHD. Materials methods Participants included 20 AGHD (11 GH-substituted 9 GH-unsubstituted) 37 healthy controls. Subjects underwent routine laboratory examinations, anthropometric measurements, body composition analysis using multi-frequency bioelectrical impedance (InBody720) measurement serum concentrations. In subjects, GH-substitution was withdrawn 2 months. Measurements were carried out right before GH-withdrawal, at end 2-month withdrawal period, 1 month after reinstituting GH-replacement therapy (GHRT). Results GH-unsubstituted demonstrated higher compared controls (p=0.03). positively correlated skeletal muscle mass, bone mineral content, total water, extracellular- intracellular water (all, p<0.01), HOMA-IR (p=0.01) C-peptide (p=0.03) but GH-withdrawal caused significant changes composition, including decreased fat-free content p<0.01); almost fully recovered GHRT. Unexpectedly, increased reinstitution (p<0.01). Changes during (r=0.80; p<0.01) (r=0.71; p=0.02). Conclusion unsubstituted might indicate severe dysregulation. Significant accompanying reinstitution, along strong correlations measures IR, suggest that could be promising GHRT-associated sensitivity.

Language: Английский

---

Post-Traumatic Hypopituitarism

Current Physical Medicine and Rehabilitation Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 18, 2024

Language: Английский

---

A Case of Secondary Growth Hormone Deficiency that Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy

Internal Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

This case report describes a patient who received hormone replacement therapy for secondary panhypopituitarism and subsequently developed diabetes. His physician decided to discontinue growth (GH) replacement, which was previously deemed contraindicated. Following the diagnosis of fatty liver, began exhibit liver damage that progressed over ensuing years, ultimately leading cirrhosis. Common factors linked cirrhosis were excluded, belief GH deficiency several years primary contributor Therefore, when treating patients with insufficiency diabetes, clinicians should carefully consider potential implications therapy.

Language: Английский

---

Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Indian Journal of Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 28(4), P. 336 - 342

Published: July 1, 2024

Abstract Multiple observation studies and meta-analysis have linked growth hormone (GH) deficiency with metabolic-dysfunction-associated steatotic liver disease (MASLD). No has analysed the efficacy safety of GH therapy on different aspects MASLD. We undertook this to address gap in knowledge. Electronic databases were searched for RCTs involving patients MASLD receiving therapy. Primary outcome was evaluate changes radiologic measures (magnetic resonance spectroscopy (MRS) ultrasonography) enzymes. Secondary outcomes alterations body composition parameters [dual-energy X-ray absorptiometry (DXA)], lipids, glycaemia side effects. From initially 1047 articles, data from three (120 patients) which fulfilled all criteria analysed. After 6 months MASLD, per cent reduction intrahepatic lipid significantly higher as compared placebo [MD -5.85% (95%CI:-11.41– -0.30); P = 0.04; I 2 63%]. Visceral adipose tissue (VAT) area (DXA) [MD-9.94 cm (95%CI:-19.04– -0.84); 0.03; 0%]. Serum insulin-like factor-1 (IGF-1) raised +166.86 ng/ml (95%CI: 79.19–254.53); < 0.0.001; 90%]. High-sensitivity C-reactive protein (hsCRP) lower -0.89 mg/L (95%CI:-1.40–-0.38); 0.0.0006; Patients had similar triglycerides [MD-1.06 (95%CI:-20.45–18.34); 0.91; 15%] fasting glucose -0.56 (95%CI:-4.67–3.55); 0.79; 39%]. Gamma-glutamyl transpeptidase -7.86 U/L (95%CI:-12.46–-3.27); 0.0008; increase new-onset hypothyroidism noted [OR 5.49 0.25–121.18); 0.28]. Short-term 6-month is associated a significant content, visceral adiposity, GGT hsCRP without any increased occurrence dysglycaemia or hypothyroidism.

Language: Английский

---

Long-term metabolic effectiveness and safety of growth hormone replacement therapy in patients with adult growth hormone deficiency: a single-institution study in Japan

Pituitary, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 19, 2024

Language: Английский

---

"Issues of Interrelationship between Growth Hormone Deficiency and Nonalcoholic Fatty Liver Disease. Literature Review"

Biomedical Journal of Scientific & Technical Research, Journal Year: 2023, Volume and Issue: 53(5)

Published: Nov. 21, 2023

Background:The role of growth hormone deficiency in the pathogenesis non-alcoholic fatty liver disease is an urgent problem and currently under research.In addition, coming years we will receive results foreign trials on HRT this category patients, which allow us to see relationship these pathologies a new way.The purpose study was significance according literature review. Material Research Methods:A review publications (RCTs, articles, reviews) PubMed, Elsevier for period from 2007 2023 performed.Results: Signaling activator transcription -5 (STAT5) Janus kinase (JAK2) have been found be critical metabolic homeostasis by preventing hepatic steatosis through regulation lipogenic genes involved FA uptake synthesis.However, STAT5 JAK2 are differentially cancer development, part due differences ROS generation clearance.Loss or (with without hyperactivated GR signaling) increased lipid accumulation.However, accelerates tumor associated with STAT3 activation oxidative damage.In contrast, delays formation. Conclusion:1.The data showed that GH, IGF-1 IGFBP-3 were fibrosis NAFLD.A low level may fibrosis, GH steatosis.2. Issues replacement therapy genetically engineered case its patients NAFLD cirrhosis centers (USA, India) require further confirmation.

Language: Английский

---